Insider sale details
According to a Form 4 filed with the Securities and Exchange Commission, Anshul Maheshwari, Chief Financial Officer of SI-Bone, Inc. (NASDAQ:SIBN), sold a total of 3,318 shares of the company’s common stock on April 2, 2026. The two transactions produced combined proceeds of $42,707, executed at weighted average prices reported between $12.8137 and $12.9228.
The filing breaks the activity into two separate trades. The first transaction comprised 1,758 shares, transacted at prices ranging from $12.52 to $13.08. The second transaction consisted of 1,560 shares, with prices spanning $12.41 to $13.10.
Post-sale holdings
After completing these sales, Maheshwari is recorded as directly owning 263,148 shares of SI-Bone common stock. That total includes 193,458 shares that are listed as issuable upon settlement of restricted stock units.
Reason for the disposition
The Form 4 indicates the share sales were executed to satisfy tax-withholding obligations associated with the vesting of restricted stock units. The filing explicitly states the transactions were not discretionary trades. The sales were carried out by Michael Pisetsky, acting as Attorney-in-Fact for Anshul Maheshwari.
Recent stock performance and company financials
The common stock has faced pressure this year, trading down 33% year-to-date, though it recorded a 6.8% gain over the past week. An analysis cited in the previous reporting notes that SI-Bone holds more cash than debt on its balance sheet and reports a strong current ratio of 8.55, even as the company was not profitable over the last twelve months.
SI-BONE Inc. also reported its fourth-quarter 2025 financial results, posting an earnings per share figure of -$0.04, which outperformed the consensus forecast of -$0.12. Revenue for the quarter was $56.3 million, beating an expected $54.7 million. The company’s revenue beat and positive cash flow were highlighted by at least one sell-side firm as factors supporting a higher price target.
Analyst reactions
Following the quarter, Truist Securities raised its price target for SI-BONE to $24, up from $23, while maintaining a Buy rating, citing the revenue beat and positive cash flow. Piper Sandler reiterated an Overweight rating with a $25.00 price target, calling attention to management’s focus on opportunities it expects will drive revenue growth and improve profitability over time.
What the filing does and does not say
The Form 4 entry documents the sale and its stated purpose - covering tax-withholding obligations related to RSU vesting - and identifies the agent who executed the transactions. The filing also specifies that the sales were not discretionary. Beyond these points, the filing does not provide further commentary on future management plans or additional insider trading intentions.